PT2240490E - Compostos orgânicos - Google Patents

Compostos orgânicos

Info

Publication number: PT2240490E
Authority: PT; Portugal
Prior art keywords: organic compounds; compounds; cyclopent; pyrazolo; imidazo
Prior art date: 2007-12-06

Application number

PT88603600T

Other languages

English (en)

Inventor

Peng Li

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-06

Filing date

2008-12-06

Publication date

2013-12-09

2008-12-06 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2013-12-09 Publication of PT2240490E publication Critical patent/PT2240490E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Anesthesiology (AREA)
Addiction (AREA)
Transplantation (AREA)

PT88603600T 2007-12-06 2008-12-06 Compostos orgânicos PT2240490E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1204007P	2007-12-06	2007-12-06

Publications (1)

Publication Number	Publication Date
PT2240490E true PT2240490E (pt)	2013-12-09

Family

ID=40755776

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT88603600T PT2240490E (pt)	2007-12-06	2008-12-06	Compostos orgânicos

Country Status (17)

Country	Link
US (3)	US8273751B2 (pt)
EP (3)	EP2698160A3 (pt)
JP (4)	JP5068857B2 (pt)
KR (2)	KR101227738B1 (pt)
CN (7)	CN104370918A (pt)
AU (1)	AU2008335811B2 (pt)
CA (2)	CA2845454C (pt)
DK (1)	DK2240490T3 (pt)
ES (1)	ES2436780T3 (pt)
HK (6)	HK1207628A1 (pt)
HR (1)	HRP20131073T1 (pt)
IL (2)	IL206096A (pt)
MX (1)	MX2010006212A (pt)
PL (1)	PL2240490T3 (pt)
PT (1)	PT2240490E (pt)
SI (1)	SI2240490T1 (pt)
WO (1)	WO2009075784A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20040066788A (ko)	2001-08-31	2004-07-27	더 락커펠러 유니버시티	프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1ｂ 매개되는 신호의 조절
CN101248050B (zh)	2005-06-06	2013-07-17	武田药品工业株式会社	有机化合物
MX2008015489A (es)	2006-06-06	2009-01-13	Intra Cellular Therapies Inc	Compuestos organicos.
US9198924B2 (en) *	2006-11-13	2015-12-01	Intra-Cellular Therapies, Inc.	Organic compounds
US9006258B2 (en)	2006-12-05	2015-04-14	Intra-Cellular Therapies, Inc.	Method of treating female sexual dysfunction with a PDE1 inhibitor
CA2707218A1 (en) *	2007-12-06	2009-06-11	Intra-Cellular Therapies, Inc.	Organic compounds
CN104370918A (zh)	2007-12-06	2015-02-25	武田药品工业株式会社	有机化合物
EP2370080A1 (en) *	2008-12-02	2011-10-05	University of Utah Research Foundation	Pde1 as a target therapeutic in heart disease
PE20110922A1 (es)	2008-12-06	2012-01-22	Intra Cellular Therapies Inc	DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
CA2740398A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
EP2358723B1 (en)	2008-12-06	2015-05-13	Intra-Cellular Therapies, Inc.	4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors
MX2011005934A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
PE20110995A1 (es)	2008-12-06	2012-02-06	Intra Cellular Therapies Inc	DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1
ES2580759T3 (es)	2008-12-06	2016-08-26	Intra-Cellular Therapies, Inc.	Compuestos orgánicos
JP2012518685A (ja)	2009-02-25	2012-08-16	イントラ−セルラー・セラピーズ・インコーポレイテッド	眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (en)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Organic compounds
WO2011016861A2 (en)	2009-08-05	2011-02-10	Intra-Cellular Therapies, Inc.	Novel regulatory proteins and inhibitors
WO2011043816A1 (en)	2009-10-08	2011-04-14	Intra-Cellular Therapies, Inc.	Phosphodiesterase 1-targeting tracers and methods
EP2576551A4 (en) *	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
EP2575817A4 (en)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
TW201206937A (en) *	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
US9371327B2 (en)	2010-05-31	2016-06-21	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
WO2012171016A1 (en)	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Organic compounds
BR112014031731B1 (pt)	2012-06-18	2022-12-06	Dart Neuroscience (Cayman) Ltd	Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos
AR091507A1 (es) *	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
JP6549040B2 (ja)	2013-02-17	2019-07-24	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	新規使用
CA2906640C (en)	2013-03-15	2021-07-20	Intra-Cellular Therapies, Inc.	Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
EP2968338B1 (en)	2013-03-15	2019-01-09	Intra-Cellular Therapies, Inc.	Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
BR112015032132B1 (pt) *	2013-06-21	2022-03-15	Intra-Cellular Therapies, Inc	Composto de base livre, composto na forma cristalina, processo para preparar uma forma cristalina de base livre e processo para preparar uma forma cristalina de sal de monofosfato do composto a
WO2015106032A1 (en)	2014-01-08	2015-07-16	Intra-Cellular Therapies, Inc.	Products and pharmaceutical compositions
WO2015196186A1 (en) *	2014-06-20	2015-12-23	Intra-Cellular Therapies, Inc.	Organic compounds
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
WO2016022825A1 (en)	2014-08-07	2016-02-11	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10005789B2 (en)	2014-08-07	2018-06-26	Intra-Cellular Therapies, Inc.	Organic compounds
ES2745819T3 (es)	2014-08-07	2020-03-03	Intra Cellular Therapies Inc	Derivados de imidazo[1,2-a]-pirazolo[4,3-e]-pirimidin-4-ona con actividad inhibidora de la PDE1
IL292225B2 (en)	2014-09-17	2024-12-01	Intra Cellular Therapies Inc	Derivatives of 5,7,7-trimethyl-[2H]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5H)-one and pharmaceutical compositions comprising them.
CN107205999B (zh)	2014-12-06	2021-08-03	细胞内治疗公司	有机化合物
RU2702732C1 (ru)	2014-12-06	2019-10-10	Интра-Селлулар Терапиз, Инк.	Органические соединения
US10287269B2 (en)	2015-03-26	2019-05-14	Merck Sharp & Dohme Corp.	Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
WO2017172795A1 (en)	2016-03-28	2017-10-05	Intra-Cellular Therapies, Inc.	Novel compositions and methods
US11291666B2 (en)	2016-09-12	2022-04-05	Intra-Cellular Therapies, Inc.	Uses
CN110337437B (zh)	2016-12-28	2023-02-03	达特神经科学有限公司	作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
WO2019104285A1 (en)	2017-11-27	2019-05-31	Dart Neuroscience, Llc	Substituted furanopyrimidine compounds as pde1 inhibitors
JP7401442B2 (ja)	2018-01-31	2023-12-19	イントラ－セルラー・セラピーズ・インコーポレイテッド	新規使用
CN112189013A (zh)	2018-05-25	2021-01-05	细胞内治疗公司	有机化合物
MX2021004531A (es) *	2018-10-21	2021-09-10	Intra Cellular Therapies Inc	Nuevos usos.
US12396992B2 (en)	2019-01-07	2025-08-26	Intra-Cellular Therapies, Inc.	Organic compounds
US11628171B2 (en)	2019-03-13	2023-04-18	Children's Medical Center Corporation	Method for treating brain or nerve injury
WO2020210614A1 (en) *	2019-04-12	2020-10-15	Intra-Cellular Therapies, Inc.	Organic compounds
US12410175B2 (en)	2019-09-03	2025-09-09	Intra-Cellular Therapies, Inc.	Compounds
JP2023505054A (ja) *	2019-11-27	2023-02-08	イントラ－セルラー・セラピーズ・インコーポレイテッド	処置方法
US12435093B2 (en)	2020-05-06	2025-10-07	Intra-Cellular Therapies, Inc.	Free base crystals
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease
JP2024531548A (ja) *	2021-09-03	2024-08-29	イントラ－セルラー・セラピーズ・インコーポレイテッド	共結晶
EP4472638A2 (en) *	2022-01-31	2024-12-11	Intra-Cellular Therapies, Inc.	Salt crystals

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666908A (en)	1985-04-05	1987-05-19	Warner-Lambert Company	5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
KR920004437B1 (ko)	1989-09-12	1992-06-05	삼성전자 주식회사	금전등록기의 거래선 관리방법
IL98559A0 (en)	1990-06-21	1992-07-15	Schering Corp	Polycyclic guanine derivatives
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
EP0686157A1 (en)	1993-02-26	1995-12-13	Schering Corporation	2-benzyl-polycyclic guanine derivatives and process for preparing them
US5824683A (en)	1995-11-28	1998-10-20	Schering Corporation	2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
SE9701398D0 (sv)	1997-04-15	1997-04-15	Astra Pharma Prod	Novel compounds
IT1291372B1 (it)	1997-05-21	1999-01-07	Schering Plough S P A	Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en)	1997-10-17	2000-01-11	The Rockfeller University	Method of treating psychosis and/or hyperactivity
GB9722520D0 (en)	1997-10-24	1997-12-24	Pfizer Ltd	Compounds
DE19931206A1 (de) *	1999-07-07	2001-01-11	Stief Christian	Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
DZ3218A1 (fr)	1999-10-11	2001-04-19	Pfizer	Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase
IL152925A (en) *	1999-10-21	2010-04-15	Pfizer	Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
WO2001078711A2 (en)	2000-04-19	2001-10-25	Lilly Icos, Llc.	Pde-v inhibitors for treatment of parkinson's disease
SE0102315D0 (sv)	2001-06-28	2001-06-28	Astrazeneca Ab	Compounds
JP4450365B2 (ja)	2001-08-28	2010-04-14	シェーリングコーポレイション	多環式グアニンホスホジエステラーゼｖ阻害剤
KR20040066788A (ko)	2001-08-31	2004-07-27	더 락커펠러 유니버시티	프스포다이에스터레이즈 활성 및 뇌에서프스포다이에스터레이즈 1ｂ 매개되는 신호의 조절
MXPA04004370A (es)	2001-11-09	2004-08-11	Schering Corp	Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
EP1476200A4 (en)	2002-02-21	2008-08-13	Univ Rockefeller	COMPOSITION AND METHOD FOR REGULATING CALCIUM DEPENDENT SIGNALING IN THE BRAIN
WO2004087906A1 (en)	2003-03-31	2004-10-14	Pfizer Products Inc.	Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
CN1802177A (zh) *	2003-04-01	2006-07-12	应用研究系统Ars股份公司	用于不育症中的磷酸二酯酶抑制剂
CA2517487A1 (en) *	2003-04-01	2004-10-14	Applied Research Systems Ars Holding N.V.	Inhibitors of phosphodiesterases in infertility
CN101248050B (zh) *	2005-06-06	2013-07-17	武田药品工业株式会社	有机化合物
WO2007025103A2 (en)	2005-08-23	2007-03-01	Intra-Cellular Therapies, Inc.	Organic compounds for treating reduced dopamine receptor signalling activity
MX2008015489A (es)	2006-06-06	2009-01-13	Intra Cellular Therapies Inc	Compuestos organicos.
US9198924B2 (en)	2006-11-13	2015-12-01	Intra-Cellular Therapies, Inc.	Organic compounds
US9006258B2 (en)	2006-12-05	2015-04-14	Intra-Cellular Therapies, Inc.	Method of treating female sexual dysfunction with a PDE1 inhibitor
CN104370918A (zh)	2007-12-06	2015-02-25	武田药品工业株式会社	有机化合物
CA2707218A1 (en)	2007-12-06	2009-06-11	Intra-Cellular Therapies, Inc.	Organic compounds
MX2011005934A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
EP2358723B1 (en)	2008-12-06	2015-05-13	Intra-Cellular Therapies, Inc.	4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors
CA2740398A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
ES2580759T3 (es)	2008-12-06	2016-08-26	Intra-Cellular Therapies, Inc.	Compuestos orgánicos
PE20110995A1 (es)	2008-12-06	2012-02-06	Intra Cellular Therapies Inc	DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1
PE20110922A1 (es)	2008-12-06	2012-01-22	Intra Cellular Therapies Inc	DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
JP2012518685A (ja)	2009-02-25	2012-08-16	イントラ−セルラー・セラピーズ・インコーポレイテッド	眼障害のためのｐｄｅ１阻害剤
WO2010132127A1 (en) *	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Organic compounds
WO2011043816A1 (en)	2009-10-08	2011-04-14	Intra-Cellular Therapies, Inc.	Phosphodiesterase 1-targeting tracers and methods
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
EP2576551A4 (en)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
EP2575817A4 (en)	2010-05-31	2014-01-08	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
US9371327B2 (en)	2010-05-31	2016-06-21	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
WO2012171016A1 (en)	2011-06-10	2012-12-13	Intra-Cellular Therapies, Inc.	Organic compounds
AR091507A1 (es)	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
CA2906640C (en)	2013-03-15	2021-07-20	Intra-Cellular Therapies, Inc.	Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors

2008
- 2008-12-06 CN CN201410545406.8A patent/CN104370918A/zh active Pending
- 2008-12-06 AU AU2008335811A patent/AU2008335811B2/en active Active
- 2008-12-06 EP EP13177860.7A patent/EP2698160A3/en not_active Withdrawn
- 2008-12-06 CN CN201410545499.4A patent/CN104370920A/zh active Pending
- 2008-12-06 CN CN201410545509.4A patent/CN104370921A/zh active Pending
- 2008-12-06 US US12/746,236 patent/US8273751B2/en active Active
- 2008-12-06 DK DK08860360.0T patent/DK2240490T3/da active
- 2008-12-06 CN CN201410545465.5A patent/CN104370919A/zh active Pending
- 2008-12-06 CA CA2845454A patent/CA2845454C/en active Active
- 2008-12-06 CA CA2707349A patent/CA2707349C/en active Active
- 2008-12-06 JP JP2010536936A patent/JP5068857B2/ja active Active
- 2008-12-06 PT PT88603600T patent/PT2240490E/pt unknown
- 2008-12-06 EP EP08860360.0A patent/EP2240490B1/en active Active
- 2008-12-06 ES ES08860360.0T patent/ES2436780T3/es active Active
- 2008-12-06 CN CN201410545520.0A patent/CN104370922A/zh active Pending
- 2008-12-06 HR HRP20131073AT patent/HRP20131073T1/hr unknown
- 2008-12-06 EP EP15152132.5A patent/EP2939676A1/en not_active Withdrawn
- 2008-12-06 KR KR1020107014663A patent/KR101227738B1/ko active Active
- 2008-12-06 SI SI200831099T patent/SI2240490T1/sl unknown
- 2008-12-06 CN CN201410545375.6A patent/CN104402893A/zh active Pending
- 2008-12-06 PL PL08860360T patent/PL2240490T3/pl unknown
- 2008-12-06 MX MX2010006212A patent/MX2010006212A/es active IP Right Grant
- 2008-12-06 WO PCT/US2008/013411 patent/WO2009075784A1/en active Application Filing
- 2008-12-06 KR KR1020117029449A patent/KR20120012831A/ko not_active Ceased
- 2008-12-06 CN CN2008801262362A patent/CN101970444A/zh active Pending
2010
- 2010-05-31 IL IL206096A patent/IL206096A/en active IP Right Grant
2012
- 2012-04-19 JP JP2012095588A patent/JP5536135B2/ja active Active
- 2012-06-01 US US13/486,264 patent/US8829008B2/en active Active
2014
- 2014-03-24 IL IL231674A patent/IL231674A0/en unknown
- 2014-04-23 JP JP2014089334A patent/JP2014148534A/ja active Pending
- 2014-08-15 US US14/461,132 patent/US9403836B2/en active Active
2015
- 2015-08-25 HK HK15108239.7A patent/HK1207628A1/xx active IP Right Revival
- 2015-08-25 HK HK15108238.8A patent/HK1207627A1/xx unknown
- 2015-08-25 HK HK15108242.2A patent/HK1207630A1/xx unknown
- 2015-08-25 HK HK15108241.3A patent/HK1207629A1/xx active IP Right Revival
- 2015-08-25 HK HK15108243.1A patent/HK1207631A1/xx unknown
- 2015-09-10 HK HK15108825.7A patent/HK1208218A1/xx active IP Right Revival
- 2015-10-14 JP JP2015203116A patent/JP2016190834A/ja active Pending

Also Published As

Publication number	Publication date
KR20100102138A (ko)	2010-09-20
US20120238589A1 (en)	2012-09-20
HK1208218A1 (en)	2016-02-26
CN104370919A (zh)	2015-02-25
ES2436780T3 (es)	2014-01-07
IL231674A0 (en)	2014-04-30
JP5068857B2 (ja)	2012-11-07
AU2008335811B2 (en)	2012-05-17
PL2240490T3 (pl)	2014-02-28
JP2011506321A (ja)	2011-03-03
MX2010006212A (es)	2010-08-10
US8273751B2 (en)	2012-09-25
JP2016190834A (ja)	2016-11-10
KR20120012831A (ko)	2012-02-10
CA2845454A1 (en)	2009-06-18
CN104370920A (zh)	2015-02-25
HRP20131073T1 (hr)	2014-01-31
EP2698160A2 (en)	2014-02-19
US9403836B2 (en)	2016-08-02
EP2698160A3 (en)	2014-07-23
IL206096A (en)	2014-04-30
JP2012167099A (ja)	2012-09-06
CN104402893A (zh)	2015-03-11
JP5536135B2 (ja)	2014-07-02
CN104370918A (zh)	2015-02-25
EP2240490B1 (en)	2013-09-04
KR101227738B1 (ko)	2013-01-29
CA2707349C (en)	2014-05-27
CA2707349A1 (en)	2009-06-18
EP2240490A1 (en)	2010-10-20
EP2939676A1 (en)	2015-11-04
DK2240490T3 (da)	2013-12-16
HK1207629A1 (en)	2016-02-05
IL206096A0 (en)	2010-11-30
SI2240490T1 (sl)	2014-02-28
CA2845454C (en)	2017-02-07
CN101970444A (zh)	2011-02-09
JP2014148534A (ja)	2014-08-21
HK1207630A1 (en)	2016-02-05
CN104370921A (zh)	2015-02-25
HK1207628A1 (en)	2016-02-05
US20100273754A1 (en)	2010-10-28
WO2009075784A1 (en)	2009-06-18
HK1207627A1 (en)	2016-02-05
AU2008335811A1 (en)	2009-06-18
US8829008B2 (en)	2014-09-09
HK1207631A1 (en)	2016-02-05
EP2240490A4 (en)	2011-06-15
US20140357606A1 (en)	2014-12-04
CN104370922A (zh)	2015-02-25

Publication	Publication Date	Title
MX2010006212A (es)	2010-08-10	Compuestos organicos.
TN2011000247A1 (en)	2012-12-17	Organic compounds
MX2011005933A (es)	2011-12-16	Compuestos organicos.
MX352831B (es)	2017-12-11	Cristales de sal.
TN2011000245A1 (en)	2012-12-17	Organic compounds
WO2012007345A3 (en)	2012-04-12	Substituted imidazo[1,2-a]pyrimidines and -pyridines
TN2011000244A1 (en)	2012-12-17	Organic compounds
WO2006133261A3 (en)	2007-06-21	Organic compounds
GEP20135780B (en)	2013-03-11	Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
PH12013500742A1 (en)	2015-10-23	Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
CL2009000255A1 (es)	2009-08-14	Compuestos derivados de pirrolo [2,3-d] pirimidinas, con actividad inhibidora de cinasa jak1, jak2 y jak3; composicion farmaceutica; utiles en el tratamiento de enfermedades proliferativas, rechazo a trasplantes, lupus eritematoso, esclerosis multiple, artritis reumatoide, entre otras.
NZ623922A (en)	2015-09-25	Novel tricyclic compounds
IN2012DN02577A (pt)	2015-08-28
NO20075232L (no)	2007-11-28	Fremgangsmate for fremstilling av pyrido[2,3-d]pyrimidin-7-on og 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-on derivater
CO6602133A2 (es)	2013-01-18	Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas
PL1869038T3 (pl)	2009-12-31	Podstawione pochodne 5,6,7,8-tetrahydro-imidazo[1,2-a]pirydyn-2-yloaminy i ich zastosowanie do wytwarzania środków leczniczych
WO2007031977A3 (en)	2007-06-07	Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
EP1720551A4 (en)	2007-04-04	ALKALOID FORMULATIONS
IL243269B (en)	2019-06-30	Crystals of (sa9,ra6)-a9,9,8,7,a6,5-hexahydro-5-methyl-3-(phenylamino)-2- ((4-(6-fluoropyridin-2-yl)phenyl)methyl ) cyclopent[5,4]imidazo[a-2,1]pyrazolo[e-3,4]pyrimidine-4(h2)-one, their salts and a process for preparing the salts.
MX2008011576A (es)	2008-09-22	Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
UA98797C2 (en)	2012-06-25	2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl-propyl)-6,7-dihydro -1h-pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors
CY1114796T1 (el)	2016-12-14	Οργανικες ενωσεις
WO2023034965A3 (en)	2023-04-06	Co-crystals
JO2323B1 (en)	2006-06-28	Compounds of Pyrido [f-3,2] quinoxaline-8-carboxylic acid and its equivalents of pyrido [g-3,2] quinoxalin.
HK1187054A (en)	2014-03-28	Imidazo [1,2-b]pyridazine and imidazo [4,5-b]pyridine derivatives as jak inhibitors